- cafead   Jan 11, 2022 at 12:12: PM
via Welcome to Day 2 of the annual J. P. Morgan Healthcare Conference, gone virtual once more.
Here's your need to know. The deals began to flow as Amgen announced a team-up with Arrakis Therapeutics to develop a new class of RNA-targeting medicines, and Roche delivered a sizable investment in the liquid biopsy developer Freenome.
article source
Here's your need to know. The deals began to flow as Amgen announced a team-up with Arrakis Therapeutics to develop a new class of RNA-targeting medicines, and Roche delivered a sizable investment in the liquid biopsy developer Freenome.
article source